The global HIV drugs market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth in this market can be attributed to the increasing number of people living with HIV and AIDS, which is expected to increase the demand for these drugs. The increasing prevalence of HIV and AIDS has led to an increased need for treatment options that are more effective than those currently available in the market. This has led pharmaceutical companies to invest heavily in research and development activities for new drug candidates that are more effective than existing ones.
MultClass Combination Products accounted for a share of over 50% in 2017, followed by Nucleoside Reverse Transcriptase Inhibitors (NRTIs) with a share of around 30%. MultClass Combination Products are expected to continue dominating this market during the forecast period due their high efficacy rates as well as their ability to reduce viral load levels quickly. NRTIs are also anticipated to maintain their dominance due their low cost per pill and ease of use when compared with other classes such as protease inhibitors or fusion inhibitors.
-The HIV/AIDS pandemic is still a major issue in many countries, with an estimated 36.7 million people living with HIV worldwide.
-The global AIDS epidemic has been declining since the 1990s, but it is still a major public health concern in many regions of the world.
-Infection rates are highest in sub-Saharan Africa and parts of Asia, where there are large populations and limited resources to combat the disease.
-There are more than 1 million new cases of HIV infection each year worldwide, and about half of these occur among young people aged 15 to 24 years old.
-HIV drugs can be expensive for patients who do not have health insurance or other coverage for prescription drugs.
Industry Growth Insights published a new data on “HIV Drugs Market”. The research report is titled “HIV Drugs Market research by Types (Multi-Class Combination Products, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Fusion Inhibitors, Entry Inhibitors - CCR5 Co-Receptor Antagonist, HIV Integrase Strand Transfer Inhibitors), By Applications (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Players/Companies Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck”.
Scope Of The Report
Report Attributes
Report Details
Report Title
HIV Drugs Market Research Report
By Type
Multi-Class Combination Products, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Fusion Inhibitors, Entry Inhibitors - CCR5 Co-Receptor Antagonist, HIV Integrase Strand Transfer Inhibitors
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others
By Companies
Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global HIV Drugs Market Report Segments:
The global HIV Drugs market is segmented on the basis of:
Types
Multi-Class Combination Products, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Fusion Inhibitors, Entry Inhibitors - CCR5 Co-Receptor Antagonist, HIV Integrase Strand Transfer Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol-Myers Squibb
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck
Highlights of The HIV Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Multi-Class Combination Products
- Nucleoside Reverse Transcriptase Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Fusion Inhibitors
- Entry Inhibitors - CCR5 Co-Receptor Antagonist
- HIV Integrase Strand Transfer Inhibitors
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the HIV Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
HIV drugs are medications that help to treat HIV infection. These medications can help to prevent the virus from spreading and causing serious health problems. There are many different types of HIV drugs available, and each one works in a different way to fight the virus. Some HIV drugs require regular doctor visits while others can be taken as needed.
Some of the major companies in the hiv drugs market are Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck.
The hiv drugs market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. HIV Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. HIV Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. HIV Drugs Market - Supply Chain
4.5. Global HIV Drugs Market Forecast
4.5.1. HIV Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. HIV Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. HIV Drugs Market Absolute $ Opportunity
5. Global HIV Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. HIV Drugs Market Size and Volume Forecast by Type
5.3.1. Multi-Class Combination Products
5.3.2. Nucleoside Reverse Transcriptase Inhibitors
5.3.3. Non-Nucleoside Reverse Transcriptase Inhibitors
5.3.4. Protease Inhibitors
5.3.5. Fusion Inhibitors
5.3.6. Entry Inhibitors - CCR5 Co-Receptor Antagonist
5.3.7. HIV Integrase Strand Transfer Inhibitors
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global HIV Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. HIV Drugs Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global HIV Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. HIV Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global HIV Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. HIV Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global HIV Drugs Demand Share Forecast, 2019-2026
9. North America HIV Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America HIV Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America HIV Drugs Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America HIV Drugs Market Size and Volume Forecast by Type
9.7.1. Multi-Class Combination Products
9.7.2. Nucleoside Reverse Transcriptase Inhibitors
9.7.3. Non-Nucleoside Reverse Transcriptase Inhibitors
9.7.4. Protease Inhibitors
9.7.5. Fusion Inhibitors
9.7.6. Entry Inhibitors - CCR5 Co-Receptor Antagonist
9.7.7. HIV Integrase Strand Transfer Inhibitors
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America HIV Drugs Demand Share Forecast, 2019-2026
10. Latin America HIV Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America HIV Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America HIV Drugs Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America HIV Drugs Market Size and Volume Forecast by Type
10.7.1. Multi-Class Combination Products
10.7.2. Nucleoside Reverse Transcriptase Inhibitors
10.7.3. Non-Nucleoside Reverse Transcriptase Inhibitors
10.7.4. Protease Inhibitors
10.7.5. Fusion Inhibitors
10.7.6. Entry Inhibitors - CCR5 Co-Receptor Antagonist
10.7.7. HIV Integrase Strand Transfer Inhibitors
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America HIV Drugs Demand Share Forecast, 2019-2026
11. Europe HIV Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe HIV Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe HIV Drugs Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe HIV Drugs Market Size and Volume Forecast by Type
11.7.1. Multi-Class Combination Products
11.7.2. Nucleoside Reverse Transcriptase Inhibitors
11.7.3. Non-Nucleoside Reverse Transcriptase Inhibitors
11.7.4. Protease Inhibitors
11.7.5. Fusion Inhibitors
11.7.6. Entry Inhibitors - CCR5 Co-Receptor Antagonist
11.7.7. HIV Integrase Strand Transfer Inhibitors
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe HIV Drugs Demand Share, 2019-2026
12. Asia Pacific HIV Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific HIV Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific HIV Drugs Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific HIV Drugs Market Size and Volume Forecast by Type
12.7.1. Multi-Class Combination Products
12.7.2. Nucleoside Reverse Transcriptase Inhibitors
12.7.3. Non-Nucleoside Reverse Transcriptase Inhibitors
12.7.4. Protease Inhibitors
12.7.5. Fusion Inhibitors
12.7.6. Entry Inhibitors - CCR5 Co-Receptor Antagonist
12.7.7. HIV Integrase Strand Transfer Inhibitors
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific HIV Drugs Demand Share, 2019-2026
13. Middle East & Africa HIV Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa HIV Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa HIV Drugs Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa HIV Drugs Market Size and Volume Forecast by Type
13.7.1. Multi-Class Combination Products
13.7.2. Nucleoside Reverse Transcriptase Inhibitors
13.7.3. Non-Nucleoside Reverse Transcriptase Inhibitors
13.7.4. Protease Inhibitors
13.7.5. Fusion Inhibitors
13.7.6. Entry Inhibitors - CCR5 Co-Receptor Antagonist
13.7.7. HIV Integrase Strand Transfer Inhibitors
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa HIV Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global HIV Drugs Market: Market Share Analysis
14.2. HIV Drugs Distributors and Customers
14.3. HIV Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bristol-Myers Squibb
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Gilead Sciences
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. GlaxoSmithKline
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Johnson & Johnson
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Merck
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
